Byrd JC - Search Results

1

Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Muthusamy N, Breidenbach H, Andritsos L, Flynn J, Jones J, Ramanunni A, Mo X, Jarjoura D, Byrd JC, Heerema NA. Muthusamy N, et al. Among authors: byrd jc. Cancer Genet. 2011 Feb;204(2):77-83. doi: 10.1016/j.cancergen.2010.12.006. Cancer Genet. 2011. PMID: 21494579 Free PMC article.

2

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.

Perkins JG, Flynn JM, Howard RS, Byrd JC. Perkins JG, et al. Among authors: byrd jc. Cancer. 2002 Apr 1;94(7):2033-9. Cancer. 2002. PMID: 11932906 Free article.

3

Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.

Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH, Heerema NA. Byrd JC, et al. Cancer Res. 2003 Jan 1;63(1):36-8. Cancer Res. 2003. PMID: 12517774

4

Advances in the therapy of chronic lymphocytic leukemia.

Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Johnson AJ, et al. Among authors: byrd jc. Curr Opin Hematol. 2003 Jul;10(4):297-305. doi: 10.1097/00062752-200307000-00008. Curr Opin Hematol. 2003. PMID: 12799536 Review.

5

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC. Lozanski G, et al. Among authors: byrd jc. Blood. 2004 May 1;103(9):3278-81. doi: 10.1182/blood-2003-10-3729. Epub 2004 Jan 15. Blood. 2004. PMID: 14726385 Free article.

6

Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets.

Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu TH, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC, Plass C. Rush LJ, et al. Among authors: byrd jc. Cancer Res. 2004 Apr 1;64(7):2424-33. doi: 10.1158/0008-5472.can-03-2870. Cancer Res. 2004. PMID: 15059895

7

Antibody therapy for chronic lymphocytic leukemia: a promising new modality.

Lin TS, Moran M, Lucas M, Waymer S, Jefferson S, Fischer DB, Grever MR, Byrd JC. Lin TS, et al. Among authors: byrd jc. Hematol Oncol Clin North Am. 2004 Aug;18(4):895-913, ix-x. doi: 10.1016/j.hoc.2004.04.008. Hematol Oncol Clin North Am. 2004. PMID: 15325705 Review.

8

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.

Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, Grever M, Chen CS, Byrd JC. Johnson AJ, et al. Among authors: byrd jc. Blood. 2005 Mar 15;105(6):2504-9. doi: 10.1182/blood-2004-05-1957. Epub 2004 Sep 28. Blood. 2005. PMID: 15454489 Free article.

9

Chronic lymphocytic leukemia.

Byrd JC, Stilgenbauer S, Flinn IW. Byrd JC, et al. Hematology Am Soc Hematol Educ Program. 2004:163-83. doi: 10.1182/asheducation-2004.1.163. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561682 Review.

10

Antibody therapy in chronic lymphocytic leukemia.

Byrd JC. Byrd JC. Clin Adv Hematol Oncol. 2003 Feb;1(2):89-90. Clin Adv Hematol Oncol. 2003. PMID: 16224382 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

861 results

Search Page

Filters